ARQ 087: Additional Phase I/II data

Data from 12 evaluable intrahepatic cholangiocarcinoma patients with FGFR2 genetic alterations in an open-label, U.S. and Italian Phase I/II trial showed that once-daily 300 or 400 mg oral ARQ 087 le...